Friday, December 12, 2008 4:48:54 AM
http://www.shionogi.co.jp/ir_en/news/detail/e_081212.pdf
1. The price is per tablet (good) which is 676.4 yen per tablet (about 7.5 USD). At the upper dose (which is lower then what it would be in the high dose of capacity) that would be 9 tablets a day which works out to about 25K per year (for a fully compliant patient).
Dan Welch had said he expected the price to be significantly lower then what it might be in the US. I don't understand why that would be the case but if the pricing is the same on a mg basis in the US (at 800mg TID) price would be around 33K. So if Dan is right on pricing we could be looking at something in the 50k+ range? I had thought 30k +/-. Of course it will depend on how good our data is.
2. There is a post marketing surveillance.
3. The mention of fibrosis inhibiting effect is quite interesting. The drug has been studied considerably in (small) studies in numerous other fibrotic indications (see #msg-24788957 for a partial list) and I wonder if there will be some off-label use.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM